Abstract
Human epidermal growth factor receptor type 2 (HER2) over expression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Single-domain antibody fragments (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting sdAbs are very attractive vectors for TRT, especially when labeled with .-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 sdAb 2Rs15d labeled with 225Ac
Details
Original language | English |
---|
Title of host publication | Nuclear Medicine and Biology |
---|
Publisher | Elsevier |
---|
Pages | S33 |
---|
Number of pages | 1 |
---|
Volume | 97-97 |
---|
DOIs | |
---|
Publication status | Published - 21 May 2021 |
---|
Name | Nuclear Medicine and Biology |
---|
Publisher | Elsevier |
---|
Number | S33 |
---|
Volume | 96-97 |
---|
ISSN (Electronic) | 0969-8051 |
---|